Industry Briefs

Make no mistake, the race to develop and manufacture a safe alternative to chlorofluorocarbons (CECs) is a hotly contested one. But fierce competition notwithstanding, the contenders in the race have banded together to shorten one key leg of what promises to be a marathon. Eight CFC producers from around the world—Du Pont, AKZO, Allied-Signal, Atochem, Daikin, ISC Chemicals, Pennwalt, and Solvay and Co—have agreed to share toxicity test information on HCFC-1 41 b, one CFC alternativ

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Make no mistake, the race to develop and manufacture a safe alternative to chlorofluorocarbons (CECs) is a hotly contested one. But fierce competition notwithstanding, the contenders in the race have banded together to shorten one key leg of what promises to be a marathon. Eight CFC producers from around the world—Du Pont, AKZO, Allied-Signal, Atochem, Daikin, ISC Chemicals, Pennwalt, and Solvay and Co—have agreed to share toxicity test information on HCFC-1 41 b, one CFC alternative. By coordinating the $2 million-to-$3 million research, the companies hope to have results in five years rather than six or seven.

Meanwhile, the eight firms are battling to be the first to develop the processes by which alternatives will be manufactured. But a Du Pont spokesperson admits that the companies are taking a gamble by investigating manufacturing procedures before toxicity testing is completed. If the toxicity tests reveal the alternatives as carcinogenic, much time ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies